Results 11 to 20 of about 281,748 (215)
PLoS ONE, 2020 The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak +8 more
doaj +2 more sources
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views [PDF]
Leukemia, 2021 Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that exceeds 35 years in young patients, but its natural history might be interrupted by thrombotic, fibrotic, or leukemic events, with respective 20-year rates of 26%,
Ayalew Tefferi +2 more
openalex +2 more sources
Haematologica, 2020 We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2).
Anders Lindholm Sørensen +19 more
doaj +2 more sources
Haematologica, 2019 Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children ...
Jean-Christophe Ianotto +5 more
doaj +2 more sources
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b [PDF]
Leukemia, 2022 TO THE EDITOR: Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2 V617F allele burden [1 – 3].
Jean‐Jacques Kiladjian +28 more
openalex +2 more sources
Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics
Acta Dermato-Venereologica, 2018 Aquagenic pruritus is one of the main clinical features of polycythemia vera. The aim of this study was to analyse the clinical characteristics of aquagenic pruritus.
Edyta Lelonek +3 more
doaj +2 more sources
Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea [PDF]
Cancer, 2022 Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease‐progression is unknown.
Alberto Álvarez‐Larrán +29 more
openalex +2 more sources
Givinostat: an emerging treatment for polycythemia vera
Expert Opinion on Investigational Drugs, 2020 Introduction Polycythemia vera (PV), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 mutation.
Helen T. Chifotides +2 more
openalex +3 more sources
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
American journal of hematology/oncology, 2023 Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and ...
A. Tefferi, T. Barbui
semanticscholar +1 more source
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.
NEJM Evidence, 2023 Ropeginterferon for Patients with Polycythemia VeraPatients with low-risk polycythemia vera were randomly assigned to receive ropeginterferon alfa-2b and phlebotomy or phlebotomy alone.
T. Barbui +37 more
semanticscholar +1 more source